Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Cazzola

Showing results (591-600 of 645) with videos related to

Pageof 65
Sort By:
Haematologica|November 9, 2014
The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infectionLuca Arcaini, Davide Rossi, Marco Lucioni, et al.
International Journal of Cancer|November 9, 2015
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosisSimona Salati, Roberta Zini, Simona Nuzzo, et al.
Blood|August 7, 2014
miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesisRuggiero Norfo, Roberta Zini, Valentina Pennucci, et al.
British Journal of Cancer|January 11, 2017
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasmsMichela Romano, Matteo Giovanni Della Porta, Anna Gallì, et al.
Haematologica|April 23, 2016
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trialSrdan Verstovsek, Alessandro M Vannucchi, Martin Griesshammer, et al.
American Journal of Hematology|March 31, 2012
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH SymposiumOmar Abdel-Wahab, Animesh Pardanani, Olivier A Bernard, et al.
Blood|July 15, 2011
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5qPierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, et al.
American Journal of Hematology|April 5, 2012
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPNElisabetta Antonioli, Paola Guglielmelli, Lisa Pieri, et al.
Blood|January 28, 2015
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adultsMichael R Savona, Luca Malcovati, Rami Komrokji, et al.
Blood|August 28, 2013
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNetLuca Malcovati, Eva Hellström-Lindberg, David Bowen, et al.
Pageof 65

Showing results (591-600 of 645) with videos related to

Sort By:
Pageof 65
Haematologica|November 9, 2014
The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infectionLuca Arcaini, Davide Rossi, Marco Lucioni, et al.
International Journal of Cancer|November 9, 2015
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosisSimona Salati, Roberta Zini, Simona Nuzzo, et al.
Blood|August 7, 2014
miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesisRuggiero Norfo, Roberta Zini, Valentina Pennucci, et al.
British Journal of Cancer|January 11, 2017
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasmsMichela Romano, Matteo Giovanni Della Porta, Anna Gallì, et al.
Haematologica|April 23, 2016
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trialSrdan Verstovsek, Alessandro M Vannucchi, Martin Griesshammer, et al.
American Journal of Hematology|March 31, 2012
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH SymposiumOmar Abdel-Wahab, Animesh Pardanani, Olivier A Bernard, et al.
Blood|July 15, 2011
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5qPierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, et al.
American Journal of Hematology|April 5, 2012
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPNElisabetta Antonioli, Paola Guglielmelli, Lisa Pieri, et al.
Blood|January 28, 2015
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adultsMichael R Savona, Luca Malcovati, Rami Komrokji, et al.
Blood|August 28, 2013
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNetLuca Malcovati, Eva Hellström-Lindberg, David Bowen, et al.
Pageof 65